Showing results (1981-1990 of 5,702) with videos related to
Sort By:
Pageof 571
The Oncologist|June 14, 2018
Reflections on the Boston Marathon from a Breast Cancer Oncologist (or, Why I Just Don't Quit)Amy H ComanderThe Oncologist|August 8, 2018
10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal CarcinomaLei Chen, Yuan Zhang, Shu-Zhen Lai, et al.The Oncologist|May 24, 2017
First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based TherapyHánah N Rier, Mark-David Levin, Joost van Rosmalen, et al.The Oncologist|May 24, 2017
Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality TherapyKatherine A Scilla, Søren M Bentzen, Vincent K Lam, et al.The Oncologist|May 28, 2017
Pulmonary Function Changes After Radiotherapy for Lung or Esophageal Cancer: A Systematic Review Focusing on Dose-Volume ParametersAnne G H Niezink, Renske A de Jong, Christina T Muijs, et al.The Oncologist|March 16, 2010
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancersJacqueline Lehmann-Che, Fabrice André, Christine Desmedt, et al.The Oncologist|March 19, 2010
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncologyAmy E McKee, Ann T Farrell, Richard Pazdur, et al.The Oncologist|March 19, 2010
Ethical and value issues in insurance coverage for cancer treatmentDan W BrockThe Oncologist|March 19, 2010
Uncertainty in assessing value of oncology treatmentsC Daniel Mullins, Russ Montgomery, Sean TunisThe Oncologist|March 19, 2010
Of value: A discussion of cost, communication, and evidence to improve cancer careAdam SchickedanzPageof 571